Dried blood spot testing: A novel approach for the therapeutic drug monitoring of ziprasidone-treated patients

Bioanalysis

Volumn 6, Issue 11, 2014, Pages 1487-1495

  Mercolini, Laura ^a   Mandrioli, Roberto ^a   Protti, Michele ^a   Conca, Andreas ^b   Albers, Lawrence J ^c   Raggi, Maria Augusta ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Health Agency of South Tyrol   (Italy)

^c VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZIPRASIDONE; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ACCURACY; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRIED BLOOD SPOT TESTING; DRUG DETERMINATION; DRUG MONITORING; DRUG STRUCTURE; FEASIBILITY STUDY; FEMALE; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; RELIABILITY; SCHIZOPHRENIA; VALIDATION PROCESS; LIQUID CHROMATOGRAPHY; PROCEDURES; TANDEM MASS SPECTROMETRY;

BLOOD SPECIMEN COLLECTION; CHROMATOGRAPHY, LIQUID; DRIED BLOOD SPOT TESTING; DRUG MONITORING; HUMANS; PIPERAZINES; SCHIZOPHRENIA; TANDEM MASS SPECTROMETRY; THIAZOLES;

EID: 84904616719     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.14.3     Document Type: Article

References (43)

1. Attard A, Taylor DM. Comparative effectiveness of atypical antipsychotics in schizophrenia:what have real-world trials taught us? CNS Drugs 26, 491-508 (2006).
2. Drugs@FDA. Geodon approval letter (NDA 020825). www.accessdata.fda.gov/ drugsatfdadocs/appletter/2001/20825ltr.pdf
3. Kongsamut S, Kang J, Chen XL et al. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur. J. Pharmacol. 450, 37-41 (2002).
4. Mamo D, Kapur S, Shammi CN, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am. J. Psychiatry 161, 818-825 (2004).
5. Schmidt AW, Lebel LA, Howard Jr HR, et al. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur. J. Pharmacol. 425, 197-201 (2001).
6. Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone:receptor- binding properties and real-world psychiatric practice. J. Clin. Psychiatry 64, 6-12 (2003).
7. Pfizer Inc. Geodon Prescribing Information, Document LAB-0273-21.0. http://labeling.pfizer.com/ShowLabeling.aspx?id=584
8. Hiemke C, Baumann P, Bergemann N, et al. The AGNPTDM expert group consensus guidelines:therapeutic drug monitoring in psychiatry, update 2011. Pharmacopsychiatry 44, 195-235 (2011).
9. Prakash C, Kamel A, Gummerus J, Wilner K. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metab. Dispos. 25, 863-872 (1997).
10. Kelly DL, Love RC. Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations. Psychopharmacol. Bull. 35, 66-79 (2001).
11. Raggi MA, Mandrioli R, Sabbioni C, et al. Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions. Curr. Med. Chem. 11, 279-296 (2004).
12. Patteet L, Morrens M, Maudens KE, et al. Therapeutic drug monitoring of common antipsychotics. Ther. Drug Monit. 34, 629-651 (2012).
13. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM Expert Group consensus guidelines:therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 37, 243-265 (2004).
14. Raggi MA, Mandrioli R, Pucci V, et al. Advances in therapeutic drug monitoring of atypical antipsychotic drugs. Med. Chem. Rev. 1, 299-316 (2004).
15. Raggi MA. Therapeutic drug monitoring:chemical-clinical correlations of atypical antipsychotic drugs. Curr. Med. Chem. 9, 1397-1409 (2002).
16. Sjoqvist F, Eliasson E. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine:focus on antidepressants. Clin. Pharmacol. Ther. 81, 899-902 (2007).
17. Perry PJ. Therapeutic drug monitoring of atypical antipsychotics. CNS Drugs 13, 167-171 (2004).
18. Conca A, Schmidt E, Pastore M, et al. Therapeutic drug monitoring in Italian psychiatry. Pharmacopsychiatry 44, 259-262 (2011).
19. Merli R, Haefele E. Therapeutic drug monitoring use in clinical practice of a mental health service. Pharmacopsychiatry 21, A12-A12 (2011).
20. Mercolini L, Mandrioli R, Raggi MA, et al. Analysis of cocaine and two metabolites in dried blood spots by liquid chromatography with fluorescence detection:a novel test for cocaine and alcohol intake. J. Chromatogr. A 1217, 7242-7248 (2010).
21. Mercolini L, Mandrioli R, Raggi MA, et al. Dried blood spots: liquid chromatography-mass spectrometry analysis of Δ9-tetrahydrocannabinol and its main metabolites. J. Chromatogr. A 1271, 33-40 (2013).
22. Suckow RF, Fein M, Correll CU, et al. Determination of plasma ziprasidone using liquid chromatography with fluorescence detection. J. Chromatogr. B 799, 201-208 (2004).
23. Sachse J, Hartter S, Hiemke C. Automated determination of ziprasidone by HPLC with column switching and spectrophotometric detection. Ther. Drug. Monit. 27, 158-162 (2005).
24. Al Dirbashi OY, Aboul-Enein HY, Al-Odaib A, et al. Rapid liquid chromatography-tandem mass spectrometry method for quantification of ziprasidone in human plasma. Biomed. Chromatogr. 20, 365-368 (2006).
25. Kirchherr H, Kühn-Velten WN. Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry:a multi-level, singlesample approach. J. Chromatogr. B 843, 100-113 (2006).
26. Zhang G, Terry AV Jr, Bartlett MG. Simultaneous determination of five antipsychotic drugs in rat plasma by high performance liquid chromatography with ultraviolet detection. J. Chromatogr. B. 856, 20-28 (2007).
27. Aravagiri M, Marder SR, Pollock B. Determination of ziprasidone in human plasma by liquid chromatography-electrospray tandem mass spectrometry and its application to plasma level determination in schizophrenia patients. J. Chromatogr. B 847, 237-244 (2007).
28. Zhang G, Terry AV Jr, Bartlett MG. Liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat plasma. Rapid Commun. Mass Spectrom. 21, 920-928 (2007).
29. Zhang G, Terry AV Jr, Bartlett MG. Determination of the lipophilic antipsychotic drug ziprasidone in rat plasma and brain tissue using liquid chromatography-tandem mass spectrometry. Biomed. Chromatogr. 22, 770-778 (2008).
30. Hasselstrm J. Quantification of antidepressants and antipsychotics in human serum by precipitation and ultra high pressure liquid chromatography- tandem mass spectrometry. J. Chromatogr. B 879, 123-128 (2011).
31. Gupta VK, Agarwal S, Singhal B. Potentiometric assay of antipsychotic drug (ziprasidone hydrochloride) in pharmaceuticals, serum and urine. Int. J. Electrochem. Sci. 6, 3036-3056 (2011).
32. Garcia MS, Ortuño JA, Cuartero M, et al. Use of a new ziprasidone-selective electrode in mixed solvents and its application in the analysis of pharmaceuticals and biological fluids. Sensors 11, 8813-8825 (2011).
33. Zhang G, Terry AV Jr, Bartlett MG. Sensitive liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue. J. Chromatogr. B 858, 276-281 (2007).
34. United States Pharmacopeia. 32th Edition. United States Pharmacopeial Convention, MD, USA, 734 (2009).
35. Shah VP, Midha KK, Findlay JWA, et al. Bioanalytical method validation-a revisit with a decade of progress. Pharm. Res. 17, 1551-1557 (2000).
36. Mandrioli R, Mercolini L, Raggi MA, et al. Analysis of risperidone and 9-hydroxyrisperidone in human plasma, urine and saliva by MEPS-LC-UV. J. Chromatogr. B 879, 167-173 (2011).
37. Mercolini L, Grillo M, Raggi MA, et al. Simultaneous analysis of classical neuroleptics, atypical antipsychotics and their metabolites in human plasma. Anal. Bioanal. Chem. 388, 235-243 (2007).
38. Mercolini L, Protti M, Raggi MA, et al. A fast and feasible microextraction by packed sorbent (MEPS) procedure for HPLC analysis of the atypical antipsychotic ziprasidone in human plasma. J. Pharmaceut. Biomed. 88, 467-471 (2014).
39. Edelbroek PM, van der Heijden J, Stolk LML. Dried blood spot methods in therapeutic drug monitoring:methods, assays, and pitfalls. Ther. Drug Monit. 31, 327-336 (2009).
40. Arora R, Hudson W, Boguszewski P. Hematocrit and its impact on quantitative bioanalysis using dried blood spot technology. Agilent application note 990-9630EN (2011). www.chem.agilent.com/Library/applications/5990-9630EN. pdf
41. Hudson W, Yong B, Boguszewski P, Arora R. Homogeneity of Dried Blood Spots, Agilent application note 5990-8306EN (2011). www.chem.agilent.com/ Library/applications/5990-8306EN.pdf
42. Paixão P, Gouveia LF, Morais JA. Prediction of the in vitro intrinsic clearance determined in suspensions of human hepatocytes by using artificial neural networks. Eur. J. Pharm. Sci. 39, 310-321 (2010).
43. Walash MI, Belal F, El-Enany N, et al. Stability-indicating spectrofluorimetric method for the assay of ziprasidone in capsules. J. Fluoresc. 21, 1659-1667 (2011).